Sanofi Genzyme Co-Pay Assistance Program
The Sanofi Genzyme Co-Pay Assistance Program helps eligible individuals in the United States pay for their eligible out-of-pocket costs for Cerdelga, including co-pays, co-insurance and deductibles, regardless of financial status.
Once enrolled in the Sanofi Genzyme Co-Pay Assistance Program, Sanofi Genzyme will cover 100% of your eligible out-of-pocket Cerdelga drug costs up to the program maximum.
Regardless of financial status, the program is open to individuals who:
Have coverage or prescriptions paid for in part or full under any state or federally funded healthcare program including:
Sanofi Genzyme reserves the right to make eligibility determinations, set program benefit maximums, monitor participation, and modify or discontinue the program at any time. This program assists patients with their out-of-pocket drug costs for Cerdelga only.
Simply complete the online application available here. Helpful information to have on hand when you apply:
You can also call your Sanofi Genzyme Case Manager directly to learn more about the program and application process at 1-800-745-4447, Option 3.
Your application will be reviewed for eligibility.
If you are eligible, you will be automatically enrolled in the program. Enrollment in the program is subject to confirmation of eligibility.
Once approved, you will receive a confirmation letter and an enrollment card within 7-10 days. Contact your Sanofi Genzyme Case Manager if you do not receive this confirmation.
Your enrollment in the program is effective from the date of approval through the end of the calendar year (calendar year is January 1 through December 31).
If you are currently enrolled in our Co-Pay Assistance Program you will be automatically re-enrolled in the program for the next calendar year (January 1 through December 31) unless you decide to opt out of the program or your insurance coverage changes.
CERDELGA (eliglustat) capsules is a glucosylceramide synthase inhibitor indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.
Limitations of Use:
CERDELGA is contraindicated in EMs or IMs taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor, and in IMs or PMs taking a strong CYP3A inhibitor due to the risk of significantly increased eliglustat blood concentration, which may result in prolongation of cardiac intervals that could result in cardiac arrhythmias.
Your doctor will perform a test to help determine if CERDELGA is right for you.
CERDELGA can affect the way other medicines work and other medicines can affect how CERDELGA works. Using CERDELGA with other medicines or herbal supplements (including St. John’s Wort) may cause an increased risk of side effects, including ECG changes and irregular heart beat. Especially tell your doctor if you take medicines for fungal infections, tuberculosis, seizures, heart rhythm and rate problems, high blood pressure, or depression or other mental health problems. Your doctor may need to prescribe a different medicine, change your dose of other medicines, or change your dose of CERDELGA. Tell your doctor about any new medicines before you start taking them.
Before taking CERDELGA, tell your doctor about all of your medical conditions, including kidney or liver problems, history of heart attacks, or heart rhythm problems (including long QT syndrome). If you are pregnant or plan to become pregnant or breastfeed, talk to your physician. It is not known if CERDELGA will harm your unborn baby.
It is not known if CERDELGA is safe and effective in children.
Swallow the capsule whole, preferably with water. If you miss a dose of CERDELGA, take the next dose at the usual time. Do not take two doses of CERDELGA at the same time. Avoid eating or drinking grapefruit products while taking CERDELGA. Grapefruit products can increase the amount of CERDELGA in your body.
The most common adverse reactions (≥10%) for CERDELGA are: fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain. Call your doctor for medical advice about adverse effects.
You may report adverse effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
If you would like more information, talk with your doctor. You may also go to www.cerdelga.com for the Full Prescribing Information, including the Patient Medication Guide, or call Sanofi Genzyme at 1-800-745-4447.